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FR901533 (1, also known as WS79089B), WS79089A (2), and WS79089C (3) are polycyclic 
aromatic natural products with promising inhibitory activity to endothelin-converting enzymes. 
In this work, we isolated five tridecaketide products from Streptosporangium roseum No. 79089, 
including 1-3, benaphthamycin (4) and a novel FR901533 analogue (5). The structure of 5 was 
characterized based on spectroscopic data. Compared to the major product 2, the new compound 
5 has an additional hydroxyl group at C-12 and an extra methyl group at the 13-OH. The 
configuration of C-19 of these compounds was determined to be R using Mosher's method. A 
putative biosynthetic gene cluster for compounds 1-5 was discovered by analyzing the genome 
of S. roseum No. 79089. This 38.6-kb gene cluster contains 38 open reading frames, including 
a minimal polyketide synthase (wsaA-C), an aromatase (wsaD), three cyclases (wsaE, F and W) 
and a series of tailoring enzymes such as monooxygenases (wsaO1-O7) and methyltransferases 
(wsaM1 and M2). Disruption of the ketosynthase gene (wsaA) in this gene cluster abolished the 
production of 1-5, confirming that this gene cluster is indeed responsible for the biosynthesis 
of 1-5. A type II polyketide biosynthetic pathway was proposed for this group of natural 
endothelin-converting enzyme inhibitors.  
Key points 
• Five aromatic tridecaketides were isolated from Streptosporangium roseum No. 
79089. 
• A novel FR901533 analogue, 12-hydroxy-13-O-methyl-WS79089A, was 
characterized. 
• The absolute configuration of C-19 of FR901533 and analogues was determined. 
• The biosynthetic gene cluster of FR901533 and analogues was discovered. 
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Introduction 
Endothelin (ET) is a potent vasoconstrictor peptide released from renal endothelial and other 
cells, which exists in three isoforms, ET-1, ET-2, and ET-3 (Davenport et al. 2016). They are 
21-amino acid peptides, with ET-1 being the most abundant isoform. ETs are involved in 
maintaining the balance between vasoconstriction and vasodilation in the normal human 
cardiovascular system. However, overexpression of ETs can contribute to high blood pressure, 
which can hurt heart, general circulation and brain (Coelho et al. 2018), and leads to cancer 
(Bagnato et al. 2008), pain mediation (Smith et al. 2014), cerebral vasospasm (Cheng et al. 
2018) and other cardiovascular disorders.  
 Physiologically active ETs are formed from big ETs by endothelin-converting enzymes 
(ECEs) through the selective cleavage at the Trp21-Val/Ile22 peptide bond (Johnson et al. 1999). 
Two major forms of ECE, including ECE-1 and ECE-2, have been reported (Emoto and 
Yanagisawa 1995; Kaburagi et al. 1999). ECE-1 is the enzyme primarily responsible for the 
synthesis of active ET-1 (Whyteside et al. 2014). ET-1 plays a critical role in cardiovascular 
diseases (CVDs) such as hypertension, pulmonary hypertension, atherosclerosis, congestive 
heart failure, and myocardial infarction (Dhaun and Webb 2019; Rodríguez-Pascual et al. 
2011). Under these pathophysiological conditions, circulating ET levels in plasma, urine or 
cerebrospinal fluid are elevated (Löffler 2000). Therefore, inhibition of the ET system may have 
significant potential for the development of new CVD therapeutics. Two common approaches 
are used to inhibit ET, including blockade of the ET receptors and inhibition of ECE-1 (Hitzerd 
et al. 2020; Miyagawa and Emoto 2014). Studies in animal disease models suggested that ECE-
1 inhibitors may be used in the treatment of pulmonary hypertension, cardiac hypertrophy and 
failure, myocardial infraction, restenosis, and acute renal failure (De Lombaert et al. 2000; 
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Doggrell 2004).   
 About a half of approved small-molecule therapeutics are either natural products or 
directly derived from natural products (Newman and Cragg 2020). FR901533 (1, also known 
as WS79089B), WS79089A (2), WS79089C (3) and benaphthamycin (4) shown in Fig. 1 are 
dihydrobenzo[]naphthacenequinone natural products produced by actinomycetes (Ritzau et al. 
1997; Tsurumi et al. 1994). 1-3 have shown selective inhibitory activity to ECE, with IC50 
values of 0.14, 0.73 and 3.42 µM, respectively. Among these compounds, 1 is three times more 
potent than the well-known ECE inhibitor phosphoramidon (IC50 = 0.49 µM). Furthermore, 1-
3 have also shown great safety profiles. Acute toxicity studies in mice revealed that their LD50 
values were higher than 100 mg/kg, and did not have any toxicity until day 14 (Tsurumi et al. 
1994). Further studies showed that 1 acts as a competitive inhibitor of ECE, with a Ki value of 
8.9  10-8 M (Tsurumi et al. 1995). Animal studies revealed that 1 can protect the development 
of right ventricular overload and reduce the degree of medial thickening of pulmonary arteries 
in rats (Takahashi et al. 1998). It  reduced the conversion of big ET-1 to ET-1 in post-myocardial 
infarction rats and improved some parameters of cardiac remodeling early post-myocardial 
infarction (Martin et al. 2000). 1 was reported to decrease the blood pressure in apolipoprotein 
E (apoE)-deficient mice fed with a Western-type fat diet (Martínez-Miguel et al. 2009) and 
calcitriol-treated rats (Martínez-Miguel et al. 2014). Phenylephrine induces the expression of 
ET-1 in rat cardiac myocytes and increases the conversion of big ET-1 to ET-1. A study found 
that 1, as a specific ECE-1 inhibitor, can inhibit the phenylephrine-stimulated increase in protein 
synthesis rate by 45% (Kaburagi et al. 1999). 1 also decreased plasma renin activity, as well as 
the levels of plasma atrial natriuretic peptide, angiotensin II, and aldosterone in beagle dogs 
(Wada et al. 1999). Another study in dogs revealed that 1 decreased pulmonary capillary wedge 
pressure and increased cardiac output. This compound prevented the reduction of urine flow 
rate and urinary sodium excretion in association with an increase in the glomerular filtration 
5 
 
rate and renal plasma flow, and significantly suppressed the elevation of plasma atrial natriuretic 
peptide and aldosterone levels, which is an established prognostic factor in congestive heart 
failure. These results indicate that chronic ECE inhibition has potential for the treatment of 
congestive heart failure, not only on hemodynamics but also in the prevention of fluid retention 
(Wada et al. 2002). Therefore, this family of compounds represent promising lead compounds 
for the development of new CVD therapeutics.  
In continuation of our effort to search for new natural product for drug discovery, a new 
analogue (5) of FR901533 was isolated from Streptosporangium roseum No. 79089, along with 
the known compounds 1-4. The C-19 configuration was determined using the Mosher method. 
A putative biosynthetic gene cluster was discovered from the genome of S. roseum No. 79089, 
and its involvement in the biosynthesis of 1-5 was confirmed through gene disruption.  
Fig. 1  
 
Materıals and methods 
General equipment 
Products were analyzed and purified on an Agilent 1200 HPLC instrument with an Agilent 
Eclipse XDB-C18 column (5 μm, 250 mm × 4.6 mm). The samples were eluted with 
acetonitrile-water (5:95 to 100:0, v/v) at a flow rate of 1 mL/min for 30 min and detected at 460 
nm. ESI-MS spectra were obtained on an Agilent 6130 single quadrupole LC-MS in the 
negative mode. 1D and 2D NMR spectra were recorded in deuterated dimethyl sulfoxide 
(DMSO-d6) on a JEOL ECX-300 NMR instrument (300 MHz for 
1H NMR and 75 MHz for 13C 
NMR) or a Bruker Avance III HD Ascend-500 NMR instrument (500 MHz for 1H NMR and 
125 MHz for 13C NMR) in the Department of Chemistry and Biochemistry, Utah State 
University. The chemical shift (δ) values are given in parts per million (ppm). The coupling 
constants (J values) are reported in hertz (Hz). 
6 
 
Strains and vectors 
S. roseum No. 79089 (NRRL 2505) was obtained from the USDA Agricultural Research 
Service Culture Collection. Escherichia coli XL-1 Blue (Stratagene) and the pJET1.2 cloning 
vector (Thermo Fisher) were used for routine subcloning. E. coli ET12567 (pUZ8002) and 
pKC1139 vector were used for the gene disruption experiments. 
Media and culture conditions 
S. roseum No. 79089 and its mutants were maintained on YM (yeast extract-malt extract) agar 
plates at 28C. E. coli strains were routinely cultured in Luria-Bertani (LB) broth at 37C. MS 
(mannitol soya flour), ISP4 (international Streptomyces project medium 4), and TSB (tryptic 
soy broth) media were used in the conjugation experiments. Ampicillin (50 g/mL) and 
apramycin (50 g/mL) were added to the media appropriately for the cloning or conjugation. 
Extraction, analysis and purification of compounds 
S. roseum No. 79089 and its disruption mutant were grown on YM agar plates (with or without 
apramycin). The cultures were extracted three times with an equal volume of methanol. The 
extracts were then dried under reduced pressure and re-dissolved in methanol for LC-MS 
analysis. To isolate compounds 2-5, the cultivation of wild type S. roseum No. 79089 was scaled 
up to 1 L. The plates were maintained at 28C. After 7 days, the culture was extracted with 1 L 
of methanol three times. The extract was dried under reduced pressure. The compounds (2, 3, 
4 and 5) were purified by HPLC on a C18 reversed phase column, eluted with acetonitrile-water 
(5:95 to 100:0, v/v) at a flow rate of 1 mL/min over 30 min, yielding 29.8 mg of 2, 4.3 mg of 3, 
3.5 mg of 4, and 5.3 mg of 5. 
Preparation of (S)-MTPA (2S) and (R)-MTPA (2R) esters 
1 mg of 2 was transferred into one clean and completely dry NMR tube. Anhydrous pyridine-
d5 (0.4 mL) and R-(+)--methoxy--(trifluoromethyl) phenylacetyl chloride  [(R)-MTPA-Cl] 
7 
 
were added to the NMR tube quickly, and the NMR tube was shaken carefully to evenly mix 
the sample with (R)-MTPA-Cl. The reaction mixture was allowed to stand at room temperature 
for 12 hours to yield the corresponding (S)-MTPA ester 2S. Similarly, 1 mg of 2 was reacted 
with (S)-MTPA-Cl to yield the corresponding (R)-MTPA ester 2R. The 1H NMR spectra of 2S 
and 2R were collected on a Bruker Avance III HD Ascend-500 NMR instrument. The Δδ 
(δ2S−δ2R) values for proton signals near C-19 were calculated.  
Analysis of the genome of S. roseum and annotation of the putative wsa biosynthetic gene 
cluster 
The genome of S. roseum No. 79089 (GenBank accession number CP001814) has been 
previously reported (Nolan et al. 2010). Analysis of the sequenced genome was performed with 
RAST (rapid annotation using subsystem technology) (Overbeek et al. 2013). The wsa gene 
cluster was annotated with FramePlot (Ishikawa and Hotta 1999). 
Plasmid construction for the disruption of wsaA in S. roseum No. 79089   
To find out whether the discovered gene cluster is involved in the biosynthesis of 1-5, a 732-bp 
fragment of the putative ketosynthase gene wsaA was amplified from the genomic DNA of S. 
roseum No. 79089 with a 30-cycle PCR program (15 s at 98C, 15 s at 62C, and 30 s at 72C). 
The two primers were used, including 2505-KS-KO-F-EcoRI (5'-
AAGAATTCGTAACATCACGCTGTTCGAC-3') and 2505-KS-KO-R-HindIII (5'-
AAAAGCTTTGAGACCGGTCATGTGGTAG-3'). The PCR product was ligated into the 
pJET1.2 vector. The ligation product was transferred into E. coli XL1-Blue. Correct 
transformants were selected by ampicillin resistance. Colonies were picked into 5 mL of LB 
broth with 50 g/mL ampicillin, which were grown at 37C overnight. Plasmids were extracted 
and then digested with EcoRI and HindIII. The correct plasmid was named as pSW129. After 
sequencing, the wsaA fragment was excised from pSW129 and ligated into pKC1139 between 
EcoRI and HindIII to afford pSW130.   
8 
 
Conjugation and verification of the wsaA-disrupted mutant of S. roseum No. 79089   
The gene disruption plasmid pSW130 was introduced into E. coli ET12567 (pUZ8002) through 
chemical transformation. It was then introduced into S. roseum No. 79089  by E. coli–
Streptomyces conjugation, following the previously reported procedure (Bierman et al. 1992; 
Shao et al. 2012). The resulting E. coli strain (E. coli ET12567 (pUZ8002)/pSW130) was used 
as donor and S. roseum No. 79089 was the acceptor. The positive colonies were picked into 
TSB medium with 50 g/mL of apramycin after 20 days of culture on MS plates. The colonies 
were grown in TSB medium at 28C and 250 rpm for 7 days and 50 µL of the culture was 
spread on ISP4 plates with 50 g/mL of apramycin. Colonies showing up at 37C were 
considered as the recombination strain, which was further cultured on YM plate with 50 g/mL 
apramycin at 28C for product check. The mutants were confirmed by PCR analysis with a set 
of pKC1139- and genome-specific primers, including M13-47, RV-M, 2505-KS-check-1 (5'-
AGTACGTGGCCGAGCACTA-3')  and 2505-KS-check-2  (5'-
TGAGCACGGAGTCGATCG-3') using a 30-cycle PCR program (30 s at 98C, 30 s at 58C, 
and 60 s at 72C).  
 
Results  
Detection of five major dihydrobenzo[]naphthacenequinone compounds in the culture 
of S. roseum NRRL 2505 
S. roseum No. 79089 was grown in YM agar and analyzed by LC-MS. As shown in trace i of 
Fig. 2a, five major products were detected at 460 nm. These compounds had a similar maximum 
UV absorption at ~460 nm, suggesting that they are structurally related analogues. ESI-MS 
spectra (Figs. 2b-2f) of 1-5 showed the corresponding quasimolecular ion [M-H]- at m/z 505.2, 
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487.1, 529.3, 503.0 and 517.2, indicating that the molecular weights of 1-5 are 506, 488, 530, 
504 and 518, respectively.  
These compounds were purified and subjected to NMR analysis. The major product 2 
has a molecular weight of 488, which is consistent with that of WS79089A previously isolated 
from this strain. Its 1H NMR data (Table S1) are in good agreement with those reported 
(Tsurumi et al. 1994), confirming that compound 2 is WS79089A. Compound 1 has a molecular 
weight of 504, which is 18 mass units larger than 1, suggesting that a water molecule has been 
added into the structure of 2. This molecular weight is the same as that of FR901533, also named 
WS79089B, a hydrolyzed derivative of 2. Indeed, 2 can be easily converted to 1 in the presence 
of 1 N NaOH (Fig. S1), further supporting that 1 is FR901533. Similarly, the structures of 3 
and 4 were characterized as WS79089C and benaphthamycin, respectively, by a comparison of 
their 1H NMR (Table S1) with literature (Ritzau et al. 1997; Tsurumi et al. 1994).  
Fig. 2 
Characterization of 5 as 12-hydroxy-13-O-methyl-WS79089A 
The molecular weight of 5 was determined to be 518, which is 30 mass units larger than the 
major product 2. The 1D and 2D NMR of 5 were collected. The 13C NMR spectrum of 5 
revealed 28 carbon signals (Table 1), with one additional methoxy signal at C 61.3 than the 
major product 2, suggesting that one of the hydroxyl groups has been methylated. This was 
supported by the OCH3 signal at H 3.86 in the 
1H NMR (Table 1). The NMR data also revealed 
that one aromatic CH has been hydroxylated, indicated by the absence of an aromatic proton 
signal and the appearance of a low field aromatic quaternary carbon signal at C 159.0. Overall, 
the introduction of a hydroxyl group and a methyl group is consistent with the mass difference 




A further comparison of the 1H NMR data of 5 (Table 1) and 2 (Table S1) indicated that 
the major difference lies in ring A. The three free aromatic proton signals on ring A of 2 include 
two overlapped signals at H 7.71-7.88 that belong to H-10 and H-11 and a dd (doublet of 
doublets)  H-12 signal at H 7.38 (Table S1). However, there were only two aromatic proton 
signals on the same ring of 5, including a doublet at H 7.93 and a doublet at H 7.28 (Table 1). 
The coupling constant of these two doublets are 8.6 Hz, indicating that these two protons are 
ortho to each other. The signal at H 7.93 was assigned to H-10 due to its HMBC correlation to 
C-8 at C 188.0 (Fig. 3). Therefore, the other aromatic proton signal at H 7.28 must belong to 
H-11. The presence of H-10 and H-11 indicated that C-12 was hydroxylated. Furthermore, the 
HMBC correlation of the newly introduced methoxy signal at H 3.86 to C-13 at C 147.5 (Fig. 
3) confirmed that the 13-OH was methylated. Therefore, 5 was identified as 12-hydroxy-13-O-
methyl-WS79089A, which is a new compound and was named as WS79089D. 
Fig. 3 
Determination of the absolute configuration of the C-19 of WS79089A 
Compounds 1-5 have a hydroxyl group at C-19. The 19-OH of 1, 2, 4 and 5 is free, while that 
of 3 was acetylated (Fig. 1). To find the configuration of this hydroxyl group, we chose the 
major product 2 to prepare the Mosher esters. This compound was reacted with R- and S-MTPA 
chloride in deuterated pyridine in NMR tubes to afford the corresponding S- and R-
MTPA ester derivatives, 2S and 2R. The 1H NMR of these MTPA esters were collected. The 
Δ ([S−R]) values near C-19 were calculated and are shown in Fig. 4, which revealed that the 
absolute configuration of C-19 is R. This is same as C-19 in pradimicin A, whose configuration 
was found to be R as well (Napan et al. 2014). Therefore, based on our results, the 19-OH of 2 




Discovery of a putative WS79089 (wsa) biosynthetic gene cluster and the proposed 
biosynthetic pathway 
The structures of 1-5 indicated that they are synthesized through a type II polyketide 
biosynthetic pathway. By searching the reported genomic sequence of S. roseum No. 79089 in 
the NCBI GenBank, a putative type II PKS gene cluster for the biosynthesis of WS79089A 
(wsa) and analogues was located in this strain. As shown in Fig. 5a, this 38.6 kb wsa gene 
cluster contains 38 open reading frames (orfs). Their putative functions were predicted based 
on BLAST analysis of the corresponding amino acid sequences (Table 2). This gene cluster has 
3 regulatory genes (wsaR1, R2 and R3), a minimal PKS (wsaA, B and C), an aromatase (wsaD), 
three cyclases (wsaE, F and W), three ketoreductases (wsaG, T and V), two methyltransferases 
(wsaM1 and M2), and a number of other tailoring enzymes such as monooxygenases (wsaO1-
O6) and oxidoreductases (wsaJ and wsaH1-H5). There are also hypothetical proteins (wsaU1-
U3), asparagine synthetase (wsaN), and nitroreductase (wsaP) that might not be involved in the 
biosynthesis of 1-5.   
Fig. 5  
The wsa minimal PKS, including WsaA (ketosynthase), WsaB (chain length factor) and 
WsaC (acyl carrier protein), is proposed to generate a nascent 26-carbon poly-β-ketone 
intermediate 6 by condensing acetyl-CoA with 12 units of malonyl-CoA. The ketone group at 
C-11 is then reduced by a ketoreductase (WsaV or WsaT) to a hydroxyl to yield 7. The hydroxyl 
group will be removed when ring A and B are cyclized by the aromatase WsaD, which leads to 
a free proton at C-11 in the intermediate 8 and the final structure of 1-5. It was reported that in 
the biosynthesis of pradimicin A, a pentangular aromatic polyketide, the closure of rings C-E 
requires synergistic actions of two cyclases and a ring B monooxygenase (Zhan et al. 2008). 
We proposed that a similar approach is also adopted in the biosynthetic pathway of 1-5. WsaE 
and WsaF will work with WsaO3, a homolog of the pradimicin ring B monooxygenase PdmH, 
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to yield the pentangular intermediate 9. A ketoreductase, WsaV or WsaT reduces the 25-ketone 
to a hydroxyl group to afford 10. Another ketoreductase, WsaG, will reduce the 19-ketone of 
10 to a hydroxyl group to generate 11. One of the monooxygenases will introduce a hydroxyl 
group to C-5 to yield 12. Finally, methylation of the 17-OH of 12 will lead to the formation of 
1. Closure of ring F by the putative cyclase WsaW can convert 1 to the major product 2. 
Compounds 3 and 4 can be formed from 2 by acetylation at the 19-OH and hydroxylation at C-
24, respectively. 2 can also be hydroxylated at C-12 and methylated at the 13-OH to give rise 
to 5. The proposed biosynthetic pathway of 1-5 is shown in Fig. 5b. The order of the tailoring 
steps is to be determined. 
Table 2 
Confirmation of the involvement of the wsa gene cluster in WA79089 biosynthesis 
To find out whether this type II polyketide biosynthetic gene cluster is involved in the 
biosynthesis of 1 and its analogues, we conducted a gene disruption experiment. The 
ketosynthase catalyzes the decarboxylative condensation of the starter unit (acetyl-CoA) with 
the extender unit (malonyl-CoA), and thus plays an essential role in the biosynthetic process. 
We cloned a 732-bp gene fragment from the putative ketosynthase gene wsaA into pKC1139, 
yielding the disruption plasmid pSW130 (Fig. 6a). This plasmid was transferred into S. roseum 
No. 79089 through E. coli ET12567-mediated conjugation. After integration of the plasmid 
integrated into the genome, the recombination mutant was selected by apramycin resistance and 
regrown in YM with apramycin for extraction of the genomic DNA. The disruption of wsaA 
was verified by PCR. When primers 1 and 2 were used, a 1.5-kb fragment was amplified from 
the wild type, but was not obtained from the mutant due to the insertion of a large plasmid 
(pSW130) into the genome (Fig. 6b). When primers 1 and M13-47 were used, a 1.1-kb PCR 
product was obtained. This fragment could not be amplified from the wild type due to the use 
of the vector-specific primer M13-47 (Fig. 6b). Similarly, when primers 2 and RV-M were used, 
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the expected 1.09-kb fragment was amplified from the mutant, but not the wild type (Fig. 6b). 
All these results confirmed that the wsaA gene of S. roseum No. 79089 was successfully 
disrupted. The correct wsaA-disrupted mutant was grown in YM supplemented with apramycin 
and the extract was analyzed by HPLC. As shown in trace ii of Fig. 2a, the production of 1-5 
was abolished in this mutant, confirming that WsaA is essential for the production of these 
compounds in S. roseum No. 79089. Therefore, the wsa gene cluster was confirmed to be truly 




Natural products are a rich source of bioactive molecules, such as penicillin (antimicrobial), 
tetracycline (antimicrobial), paclitaxel (anticancer) and lovastatin (anticholesterol). Polyketides 
are a group of structurally and functionally diverse natural products, including 1-5 studied in 
this work. The main polyketide chain for these polycyclic aromatic compounds contains 26 
carbons, and thus are among the longest polyketide natural products that have been discovered 
in nature. Several known long aromatic polyketides have been previously reported to possess 
interesting biological activities, such as pradimicins (antifungal and antiviral) (Nakagawa et al. 
2013), benastatins (antibacterial and glutathione S-transferase inhibitory) (Jiang et al. 2020), 
and fredericamycins (antitumor) (Kotha et al. 2019).  
1-5 belong to the group of tridecaketides. Few tridecaketides have been previously 
reported. For example, accramycin A is an aromatic tridecaketide natural product isolated from 
Streptomyces sp. MA37. This compound showed antibacterial activity against Group 
B Streptococcus, with a minimum inhibitory concentration (MIC) of 27 µg/mL  (Maglangit et 
al. 2019). In addition to aromatic tridecaketides, linear polyene tridecaketides have also been 
reported. For instance, mycenaaurin A is a pigment from Mycena aurantiomarginata, which 
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consists of a tridecaketide backbone connected with two amino acid moieties. It also showed 
antibacterial activity against Bacillus pumilus (Jaeger and Spiteller 2010). 1-3 are specific 
inhibitors of ECE. 2 is identical to 1 except that its ring F is closed. It can be easily converted 
to 1 under alkaline conditions (Fig. S1). 4 was co-isolated with 2 from Streptomyces sp. HKI-
0057. It showed moderate antibacterial activity against Gram-positive bacteria such as Bacillus 
subtilis. This compound also displayed cytopathic effect against animal cells such as K-562 
human leukemia cells (Ritzau et al. 1997). 4 is the 24-hydroxylated derivative of 2. This is the 
first time this compound was isolated from S. roseum No. 79089. Furthermore, 5 was isolated 
from S. roseum No. 79089 and structurally characterized as a new member of the WS79089A 
family. This new compound is also an analogue of 2, with structural variations at C-12 and C-
13. Specifically, it is derived from 2 by the 12-hydroxylation and 13-O-methylation, attributing 
to the diverse tailoring enzymes in the wsa gene cluster. Isolation of 5 from S. roseum No. 
79089 provides a new compound for testing of the ECE inhibitory activity.   
1-5 contain a hydroxyl group at C-19. The configuration of C-19 of the major metabolite 
2 was determined to be R using the Mosher method, indicating that there is a  hydroxyl group 
at this position. Because of the same biosynthetic origin, it is believed that this is also the case 
for 1 and 3-5.  The configuration of C-19 in 1-5 is same as that reported for hexaricin A, which 
was determined to be R based on circular dichroism spectrum (Tian et al. 2016). Pradimicins 
also have a hydroxyl group at this position. We have previously determined the configuration 
of C-19 of pradimicins using a similar method (Napan et al. 2014). It was found that this carbon 
also has a R configuration, meaning that the 19-OH in pradimicins is in a  configuration. This 
hydroxyl group was introduced by a dedicated cytochrome P450 (CYP) hydroxylase (Napan et 
al. 2014). However, there are no putative CYP enzymes in this gene cluster (Table 2). Instead, 
we propose that the 19-OH is formed through the reduction of the 19-ketone group by a 
dedicated ketoreductase. PdmG was previously found to catalyze the reduction of the 19-ketone 
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to a hydroxyl group. This 19-OH is likely to be removed by dehydration to yield a double bond, 
which is then reduced to afford a single bond between C-19 and C-20, as seen in the pradimicin 
biosynthetic intermediate G-2A (Zhan et al. 2008). BLAST analysis revealed that WsaG is 
homologous to PdmG, with 56% identity and 74% similarity. Therefore, it is reasonable to 
propose that WsaG is the enzyme responsible for reducing the ketone group to hydroxyl at C-
19. 
The wsa gene cluster is highly similar to that reported for hexaricins in 
Streptosporangium sp. CGMCC 4.7309 (Tian et al. 2016). The involvement of this gene cluster 
in the biosynthesis of 1-5 was confirmed through targeted disruption of the wsaA gene (Fig. 6), 
which encodes a ketosynthase. There are three putative transcriptional regulatory genes in the 
wsa gene cluster, including wsaR1, R2 and R3. While wsaR2 sits inside the gene cluster, wsaR1 
and wsaR3 are at the two ends. The sequence of wsaR1 is similar to acnR, a tet regulatory gene 
found in the actinomycin D biosynthetic pathway from marine-derived Streptomyces 
costaricanus SCSIO ZS0073 (Liu et al. 2019). Based on the sequence homology, the other two 
regulatory genes are proposed to be a TenA family transcriptional regulator and SARP family 
transcriptional regulator, respectively. These two regulatory genes correspond to Hex17 and 
Hex1 reported in the hex gene cluster. Manipulation of regulatory genes in natural product 
biosynthetic pathways is a useful approach to enhance the yields of selected products (Fidan et 
al. 2019; Lu et al. 2017; Sun et al. 2018). Therefore, they are interesting targets to identify and 
engineer. The minimal PKS, consisting of wsaA, wsaB and wsaC, are homologous to PdmA, B 
and C in pradimicin biosynthesis, with 70%-86% similarities (Table 2). PdmA, B and C were 
previously characterized as the minimal PKS for pradimicin biosynthesis through heterologous 
expression. These three enzymes generate a 24-carbon poly--ketone chain (Zhan et al. 2008). 
WsaA, B and C are expected to create a nascent tridecaketide chain that contains 26 carbons. 
While we have not expressed these enzymes in a heterologous host, a gene disruption was 
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conducted for wsaA. Our results showed that disruption of wsaA abolished the production of 1-
5, indicating that this enzyme is essential for the assembly of the core tridecaketide structure.    
The nascent poly--ketone chain is highly reactive and is supposed to be cyclized by 
associated aromatase and cyclases immediately. However, unlike pradimicins and benastatins, 
the structures of 1-5 lack the 11-OH. This suggested that the 26-carbon poly--ketone 
intermediate is reduced at C-11. There are three putative ketoreductase genes in the wsa gene 
cluster, including wsaG, wsaV and wsaT. One of these ketoreductases is supposed to catalyze 
the reduction. The corresponding hydroxyl group at C-11 will be eliminated by dehydration 
during the cyclization and aromatization of ring A. The pradimicin biosynthetic gene cluster 
contains an aromatase (PdmD) and two cyclases (PdmK and PdmL). PdmD closes rings A and 
B of pradimicin A, and PdmK and PdmL are involved in the closure of rings C-E. In this work, 
we found that the wsa biosynthetic gene cluster also contains the corresponding genes, including 
the putative aromatase gene wsaD and cyclase genes wsaE and wsaF. However, there is an 
additional cyclase gene, wsaW, in this gene cluster. We propose that this gene might be involved 
in the closure of ring F of 2-5.  
Monooxygenases are commonly found in aromatic polyketide biosynthesis and 
contribute to the structural diversity of natural products. They can catalyze a series of reactions 
such as hydroxylation and oxidation. Monooxygenases have been reported to have a role in 
fidelity control during aromatic polyketide biosynthesis (Qin et al. 2019). In addition, these 
enzymes are known to work with other tailoring enzymes such as cyclases synergistically. For 
instance, PdmH is the ring B monooxygenase to form the quinone structure in pradimicins. This 
enzyme works with two cyclases, PdmK and PdmL, to close rings C-E to form the core 
pentangular structure of pradimicins (Zhan et al. 2008). While 2-5 have six rings, we propose 
that 1 is their precursor with a pentangular structure. There is a putative monooxygenase, 
WsaO3, in the wsa gene cluster. Its amino acid sequence shares 58% identity and 73% similarity 
17 
 
with that of PdmH. Therefore, it was proposed to have a similar function and be responsible for 
ring B quinone formation by working with two cyclases to form the pentangular structure of 1. 
There are six additional monooxygenases in this gene cluster. Some of them are proposed to 
catalyze the hydroxylation reactions such at C-6 and C-12. Methyltransferases are also common 
modifying enzymes in natural product biosynthetic pathways. These enzymes introduce methyl 
groups to various atoms such as C, O, S and N. Correspondingly, there are different methyl 
transferases such as C-methyltransferases, O-methyltransferases, S-methyltransferases and N-
methyltransferases (Pavkov-Keller et al. 2017). There are two putative O-methyltransferase 
genes (wsaM1 and wsaM2) in the wsa biosynthetic gene cluster. The structure of 1-4 contains 
a OCH3 group at C-17, while the new compound 5 has an additional methoxy group at C-13. 
Therefore, WsaM1 and WsaM2 are believed to introduce the two methyl groups to the 17-OH 
and 13-OH, respectively.  
The wsa gene cluster in Table 2 contains 38 open reading frames and it is likely some 
of these genes just sit in the gene cluster but are not involved in the biosynthesis of 1-5. It is 
also possible that the formation of certain minor compounds, such as 3, the acetylated derivative 
of 2, requires the action of an enzyme not within this gene cluster. In summary, this study 
discovered a new tridecaketide natural product, determined the configuration of C-19 of 1-5, 
and reported the gene cluster responsible for the assembly of this group of natural products. 
Therefore, this work provides valuable information for further understanding and engineering 
of this biosynthetic pathway to generate new compounds for screening of novel ECE inhibitors.       
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Table 1 1H (300 MHz) and 13C (75 MHz) NMR data for 5 in DMSO-d6. 
 
Position δH δC 
1  170.5 
2  107.5 
3  162.1 
3-OH 11.72 (1H, s)  
4  118.1 
5  127.9 
6  156.4 
6-OH 13.78 (1H, s)  
7  115.2 
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8  188.0 
9  125.0 
10 7.93 (1H, d, 8.6) 125.9 
11 7.28 (1H, d, 8.6) 121.3 
12  159.0 
12-OH 10.96 (1H, s)  
13  147.5 
13-OCH3 3.86 (3H, s) 61.3 
14  129.4 
15  182.4 
16  122.8 
17  149.9 
17-OCH3 3.93 (3H, s) 63.7 
18  143.9 
19 5.18 (1H, brs) 59.4 
20 2.95 (1H, m) 
2.71 (1H, m) 
38.2 
21  146.3 
22 6.88 (1H, s) 119.7 
23  140.9 
24 3.05 (1H, m) 
2.92 (1H, m) 
34.0 
25 4.88 (1H, m) 76.7 















TetR family transcriptional 
regulator 
AcnR [Streptomyces costaricanus]/QAR15125 64/71 
wsaO1 408 monooxygenase FlsP [Micromonospora rosaria]/ALJ99865 52/65 
wsaU1 102 Hypothetical protein 
Hypothetical protein [Streptosporangium 
minutum]/WP_086575026 
93/96 
wsaO2 151 Monooxygenase Hex33 [Streptosporangium sp. FXJ7.131]/AMK51290 99/99 
wsaH5 285 Flavin-dependent oxidoreductase Hex32 [Streptosporangium sp. FXJ7.131]/AMK51289 99/98 
wsaW 126 Cyclase Cyclase [Streptomyces sp. CNZ279]/WP_099879640 76/85 
wsaV 245 Ketoreductase Hex30 [Streptosporangium sp. FXJ7.131]/AMK51287 99/99 
wsaO3 104 Monooxygenase PdmH [Actinomadura hibisca]/ABM21754 58/73 




Hex28 [Streptosporangium sp. FXJ7.131]/AMK51285 98/99 
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wsaQ 294 NAD(P)-dependent oxidoreductase Hex27 [Streptosporangium sp. FXJ7.131]/AMK51284 98/98 
wsaF 108 Cyclase BenE [Streptomyces sp. A2991200]/CAM58796 62/76 
wsaE 150 Cyclase PdmL [Actinomadura hibisca]/ABK58685 60/73 
wsaA 422 Ketosynthase PdmA [Actinomadura hibisca]/ABM21747 77/86 
wsaB 406 Chain length factor PdmB [Actinomadura hibisca]/ABM21748 67/75 
wsaC 86 Acyl carrier protein PdmC [Actinomadura hibisca]/ABM21749 56/70 
wasD 160 Aromatase RubF [Streptomyces collinus]/AAG03070 72/79 
wsaO4 157 Monooxygenase Hex20 [Streptosporangium sp. FXJ7.131]/AMK51277 99/99 
wsaG 243 Ketoreductase PdmG [Actinomadura hibisca]/ABM21753.1 56/74 
wsaH1 541 FAD-dependent oxidoreductase TcmG [Streptomyces lydicus]/AJT61730 70/80 
wsaR2 232 
TenA family transcriptional 
regulator 
Hex17 [Streptosporangium sp. FXJ7.131]/AMK51274 98/98 
wsaU2 508 Hypothetical protein Hex16 [Streptosporangium sp. FXJ7.131]/AMK51273 99/99 
wsaI 446 Sodium:proton exchanger DacR3 [Dactylosporangium sp. SC14051]/AFU65890 62/76 
wsaU3 366 Hypothetical protein Hex14 [Streptosporangium sp. FXJ7.131]/AMK51271 95/96 
wsaJ 470 
NAD(P)/FAD-dependent 
oxidoreductase or halogenase 
Hex13 [Streptosporangium sp. FXJ7.131]/AMK51270 98/98 
wsaH2 333 Flavin-dependent oxidoreductase Hex12 [Streptosporangium sp. FXJ7.131]/AMK51269 98/98 
wsaH3 285 Flavin-dependent oxidoreductase Hex11 [Streptosporangium sp. FXJ7.131]/AMK51268 99/99 
wsaO5 415 Monooxygenase Hex10 [Streptosporangium sp. FXJ7.131]/AMK51267 98/99 
wsaM1 337 Methyltransferase TcmO [Streptomyces lydicus]/AJT61734 68/80 
wsaK 281 NAD(P)H-binding protein Hex8 [Streptosporangium sp. FXJ7.131]/AMK51265 99/99 
wsaM2 344 Methyltransferase Hex7 [Streptosporangium sp. FXJ7.131]/AMK51264 96/97 
wsaL 64 Ferredoxin Ferredoxin [Actinomadura sp. J1-007]/WP_164717208 76/88 
wsaN 619 Asparagine synthetase OxyD [Streptomyces rimosus]/AAZ78328 52/66 
wsaP 199 Nitroreductase Hex5 [Streptosporangium sp. FXJ7.131]/AMK51262 99/99 
wsaH4 490 FAD-dependent oxidoreductase Hex4 [Streptosporangium sp. FXJ7.131]/AMK51261 99/100 
wsaO6 118 Monooxygenase Hex3 [Streptosporangium sp. FXJ7.131]/AMK51260 96/96 
wsaO7 104 Monooxygenase GrhU [Actinoplanes sp. N902-109]/AGL16614 62/70 
wsaR3 621 
SARP family transcriptional 
regulator 










Fig. 1 Structures of 1-5 from S. roseum No. 79089.  
Fig. 2 LC-MS analysis of the production of 1-5 by S. roseum No. 79089. a HPLC traces (460 
nm) of the cultures of wild type (i) and wsaA-disrupted mutant (ii) strains of S. roseum No. 
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79089. b ESI-MS (-) spectrum of 1. c ESI-MS (-) spectrum of 2. d ESI-MS (-) spectrum of 3. e 
ESI-MS (-) spectrum of 4. f ESI-MS (-) spectrum of 5. 
Fig. 3 Key HMBC correlations for 5. 
Fig. 4 Δ (S-R) values for the MTPA esters of 2. 
Fig. 5 The wsa biosynthetic gene cluster (a) and proposed biosynthetic pathways (b) of 1-5.   
Fig. 6 Gene disruption of wsaA in S. roseum No. 79089. a The strategy to disrupt wsaA in S. 
roseum No. 79089 through single crossover recombination. b PCR verification of the wsaA-
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